APA (7th ed.) Citation

Urva, S., Quinlan, T., Landry, J., Ma, X., Martin, J. A., & Benson, C. T. (2022). Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical pharmacokinetics, 61(7), 1057-1067. https://doi.org/10.1007/s40262-022-01140-3

Chicago Style (17th ed.) Citation

Urva, Shweta, Tonya Quinlan, John Landry, Xiaosu Ma, Jennifer A. Martin, and Charles T. Benson. "Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide." Clinical Pharmacokinetics 61, no. 7 (2022): 1057-1067. https://doi.org/10.1007/s40262-022-01140-3.

MLA (9th ed.) Citation

Urva, Shweta, et al. "Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide." Clinical Pharmacokinetics, vol. 61, no. 7, 2022, pp. 1057-1067, https://doi.org/10.1007/s40262-022-01140-3.